Literature DB >> 22122802

Hypertrophic cardiomyopathy and ultra-endurance running - two incompatible entities?

Mathew G Wilson1, Navin Chandra, Michael Papadakis, Rory O'Hanlon, Sanjay K Prasad, Sanjay Sharma.   

Abstract

Regular and prolonged exercise is associated with increased left ventricular wall thickness that can overlap with hypertrophic cardiomyopathy (HCM). Differentiating physiological from pathological hypertrophy has important implications, since HCM is the commonest cause of exercise-related sudden cardiac death in young individuals. Most deaths have been reported in intermittent 'start-stop' sports such as football (soccer) and basketball. The theory is that individuals with HCM are unable to augment stroke volume sufficiently to meet the demands of endurance sports and are accordingly 'selected-out' of participation in such events. We report the case of an ultra-endurance athlete with 25 years of > 50 km competitive running experience, with genetically confirmed HCM; thereby demonstrating that these can be two compatible entities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122802      PMCID: PMC3243082          DOI: 10.1186/1532-429X-13-77

Source DB:  PubMed          Journal:  J Cardiovasc Magn Reson        ISSN: 1097-6647            Impact factor:   5.364


  37 in total

Review 1.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

2.  Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis.

Authors:  T Kawara; R Derksen; J R de Groot; R Coronel; S Tasseron; A C Linnenbank; R N Hauer; H Kirkels; M J Janse; J M de Bakker
Journal:  Circulation       Date:  2001-12-18       Impact factor: 29.690

3.  Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.

Authors:  Pascale Richard; Philippe Charron; Lucie Carrier; Céline Ledeuil; Theary Cheav; Claire Pichereau; Abdelaziz Benaiche; Richard Isnard; Olivier Dubourg; Marc Burban; Jean-Pierre Gueffet; Alain Millaire; Michel Desnos; Ketty Schwartz; Bernard Hainque; Michel Komajda
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

4.  Clinical significance of abnormal electrocardiographic patterns in trained athletes.

Authors:  A Pelliccia; B J Maron; F Culasso; F M Di Paolo; A Spataro; A Biffi; G Caselli; P Piovano
Journal:  Circulation       Date:  2000-07-18       Impact factor: 29.690

5.  Establishment and performance of a magnetic resonance cardiac function clinic.

Authors:  N G Bellenger; J M Francis; C L Davies; A J Coats; D J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2000       Impact factor: 5.364

6.  Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography.

Authors:  J C C Moon; N G Fisher; W J McKenna; D J Pennell
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

7.  The upper limit of physiological cardiac hypertrophy in elite male and female athletes: the British experience.

Authors:  G P Whyte; K George; S Sharma; S Firoozi; N Stephens; R Senior; W J McKenna
Journal:  Eur J Appl Physiol       Date:  2004-03-31       Impact factor: 3.078

8.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.

Authors:  James C C Moon; William J McKenna; Jane A McCrohon; Perry M Elliott; Gillian C Smith; Dudley J Pennell
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

9.  Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance.

Authors:  J A McCrohon; J C C Moon; S K Prasad; W J McKenna; C H Lorenz; A J S Coats; D J Pennell
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

10.  Prevalence of electrocardiographic abnormalities in West-Asian and African male athletes.

Authors:  M G Wilson; J C Chatard; F Carre; B Hamilton; G P Whyte; S Sharma; H Chalabi
Journal:  Br J Sports Med       Date:  2011-05-19       Impact factor: 13.800

View more
  4 in total

1.  Evaluation of the Mayo Clinic Phenotype-Based Genotype Predictor Score in Patients with Clinically Diagnosed Hypertrophic Cardiomyopathy.

Authors:  Sinead L Murphy; Jason H Anderson; Jamie D Kapplinger; Teresa M Kruisselbrink; Bernard J Gersh; Steve R Ommen; Michael J Ackerman; J Martijn Bos
Journal:  J Cardiovasc Transl Res       Date:  2016-02-25       Impact factor: 4.132

Review 2.  Review of Journal of Cardiovascular Magnetic Resonance 2012.

Authors:  Dudley J Pennell; A John Baksi; John Paul Carpenter; David N Firmin; Philip J Kilner; Raad H Mohiaddin; Sanjay K Prasad
Journal:  J Cardiovasc Magn Reson       Date:  2013-09-04       Impact factor: 5.364

Review 3.  Significance of deep T-wave inversions in asymptomatic athletes with normal cardiovascular examinations: practical solutions for managing the diagnostic conundrum.

Authors:  M G Wilson; S Sharma; F Carré; P Charron; P Richard; R O'Hanlon; S K Prasad; H Heidbuchel; J Brugada; O Salah; M Sheppard; K P George; G Whyte; B Hamilton; H Chalabi
Journal:  Br J Sports Med       Date:  2012-11       Impact factor: 13.800

Review 4.  Review of Journal of Cardiovascular Magnetic Resonance 2011.

Authors:  Dudley J Pennell; John Paul Carpenter; David N Firmin; Philip J Kilner; Raad H Mohiaddin; Sanjay K Prasad
Journal:  J Cardiovasc Magn Reson       Date:  2012-11-18       Impact factor: 5.364

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.